At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- AI software (device)
- How long the study runs
- Study runs about 22 months (dates as stated)
- About the drug or intervention
- AI software — device: icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 99 Years
- Who
- All
- Number of participants
- 1,336
- Started
- 2025-06-14
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for multiple sclerosis
- • NA - 1,336 participants
- • Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK
Who can take part?
- • Ages 18 Years to 99 Years
- • Diagnosed with multiple sclerosis
Where?
- • London - Barts Health NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS). It is also essential to monitor the treatment to see if it is working and to switch treatments if needed. Magnetic resonance imaging (MRI) is the only accepted tool to monitor how well the treatment is working. Current evaluation of brain Magnetic resonance imaging (MRI) scans requires visual inspection, of which sensitivity is degraded by human, and technical factors, such as lack of time, fatigue of radiologists, and lack of standardization of image acquisition protocols across the National Health Service (NHS). MRI-readings can be significantly enhanced by artificial intelligence (AI)-assistive software. Evidence suggests the rate of new lesion detection to be 3 - 4 times higher when using assistive software compared to visual inspection of MRI scans. In this study, an Artificial Intelligence (AI) software called "icobrain ms." developed by the company "icometrix" (Leuven, Belgium) is tested. This tool helps track MS by measuring changes in the brain using MRI scans. The AI can highlight problem areas and create reports that doctors can use to make better decisions about participants' treatment. The aim of the study is to prove that icobrain ms can be used to assist the neuro-radiologist with their visual assessment of MRI scans by a radiologist, and that it will help clinicians make more informed decisions about participants' current MS treatment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 99 Years
- Who can join: All genders
What the study is looking for
- ✓Clinically Isolated Syndrome suggestive of demyelination (CIS) or definitive diagnosis of MS.
- ✓Undergoing MRI head investigation.
- ✓On an MS DMT pathway.
- ✓Access to a smartphone, tablet or computer.
Who cannot take part
- ✗patients with Multiples Sclerosis participating in a randomly assigned controlled CTIMP (participating in a single arm...
See the full criteria
Where Is This Study? (1 UK site)
Barts Health NHS Trust
London E1 4NS, United Kingdom